Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ibd.21828 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety, Immunogenicity, and Efficacy of Cytomegalovirus Vaccines: A Systematic Review of Randomized Controlled Trials.
Vaccines (Basel)
January 2025
Department of Biomedical Sciences and Public Health, Section of Hygiene, Preventive Medicine and Public Health, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Cytomegalovirus (CMV) is widespread and mostly causes asymptomatic infections in immunocompetent hosts, but it may lead to severe and life-threatening diseases in immunocompromised individuals, such as transplant patients and congenitally infected children, representing a significant public health concern. Although there are no licensed CMV vaccines, the development of a CMV vaccine is considered a high priority due to its potential to reduce the burden associated with CMV-related complications, and several approaches are under investigation. The objective of this systematic review was to synthesize the evidence on various CMV vaccines currently under clinical development.
View Article and Find Full Text PDFWhat intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients.
Intensive Care Med
January 2025
Medical Intensive Care Unit, AP-HP, Saint-Louis University Hospital, Paris, France.
Purpose: Advances in therapeutic care are leading to an increase in the number of patients living with overt immunosuppression. These patients are at risk of cytomegalovirus (CMV) infection and disease that can lead to or develop during ICU admission. This manuscript aims to describe the clinical presentation, risk factors, and management of CMV infection and disease in this patient population.
View Article and Find Full Text PDFAuditory and Vestibular Involvement in Congenital Cytomegalovirus Infection.
Pathogens
November 2024
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Congenital cytomegalovirus infection (cCMV) is a frequent cause of non-hereditary sensorineural hearing loss (SNHL) and developmental disabilities. The contribution of cCMV to childhood hearing loss has been estimated to be about 25% of all hearing loss in children at 4 years of age. Although the vestibular insufficiency (VI) in cCMV has not been well-characterized and therefore, underestimated, recent studies suggest that VI is also frequent in children with cCMV and can lead to adverse neurodevelopmental outcomes.
View Article and Find Full Text PDFCytomegalovirus infection of the fetal brain: intake of aspirin during pregnancy blunts neurodevelopmental pathogenesis in the offspring.
J Neuroinflammation
November 2024
Institut de Neurobiologie de la Méditerranée (INMED), Inserm, UMR1249, Parc Scientifique de Luminy, Aix-Marseille University, BP13, 13273, Marseille Cedex 09, France.
Background: Congenital cytomegalovirus (CMV) infections represent one leading cause of human neurodevelopmental disorders. Despite their high prevalence and severity, no satisfactory therapy is available and pathophysiology remains elusive. The pathogenic involvement of immune processes occurring in infected developing brains has been increasingly documented.
View Article and Find Full Text PDFHaploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.
Bone Marrow Transplant
January 2025
Department of Hematology, Sichuan Provincial People's Hospital, Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Article Synopsis
- A study assessed the safety and effectiveness of a new haploidentical stem cell transplant (haplo-SCT) protocol in 312 patients with blood cancers, leading to promising outcomes.
- The protocol replaced certain treatments and shortened conditioning duration, resulting in quick recovery times (11 days for neutrophils and platelets) and low graft rejection rates (0.96%).
- Findings indicated manageable side effects, with moderate rates of acute and chronic GVHD, low infection rates, and a 4-year overall survival rate of 78.9%, positioning the novel haplo-SCT as a viable treatment option.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!